QuidelOrtho to Report Second Quarter 2026 Financial Results
QuidelOrtho to Report Second Quarter 2026 Financial Results PR Newswire SAN DIEGO, July 24, 2026
QDEL - QuidelOrtho Corporation
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$12.25
DETAILS
HIGH:
$12.50
LOW:
$12.00
MEDIAN:
$12.25
CONSENSUS:
$12.25
DOWNSIDE:
23.68%
Stock News
QuidelOrtho to Report Second Quarter 2026 Financial Results
SAN DIEGO, July 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a leading global provider of diagnostic solutions, announced today that it will report its financial results for the second quarter 2026 ended June 28, 2026, after the market closes on Thursday, August 6, 2026. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m.
Reasons to Add QuidelOrtho Stock in Your Portfolio for Now
QDEL's strong portfolio, cost-saving progress and mixed first-quarter results support growth, though respiratory reliance remains a risk.
Beyond Fentanyl: How the Drug Crisis Is Changing
SAN DIEGO, July 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 59 of its Science Bytes podcast examining how the drug overdose landscape continues to evolve and what laboratory and emergency department professionals need to know to support patient care. Based on new guidance from the Association for Diagnostics and Laboratory Medicine (ADLM), the episode explores the growing complexity of toxicology testing amid counterfeit medications, polysubstance use and emerging synthetic opioids.
Kaskela Law Firm Announces Investigation of QuidelOrtho Corp. (QDEL) and Encourages Long-Term QDEL Shareholders with Investment Losses to Contact the Firm
Investor litigation firm [url="]Kaskela Law[/url] announces that it is investigating QuidelOrtho Corporation (Nasdaq: QDEL) (âQuidelOrthoâ) on behalf of th
Kaskela Law Firm Announces Investigation of QuidelOrtho Corp. (QDEL) and Encourages Long-Term QDEL Shareholders with Investment Losses to Contact the Firm
PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/case/quidelortho-corp/ Recently a securities fraud complaint was filed against QuidelOrtho on behalf of certain investors who purchased shares of the company's stock between February 17, 2022 and April 1, 2024 (the “Wrongdoing Peri.
4 Medical Products Stocks Poised to Win Despite Industry Headwinds
Terumo, QuidelOrtho, Lumexa Imaging and BrainsWay are tackling industry headwinds through innovation, pricing and execution as healthcare demand stays resilient.
QuidelOrtho Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL)("QuidelOrtho"), a leading global provider of diagnostic solutions, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of restricted stock units ("RSUs") with respect to 356,555 shares of the Company's common stock (the "Inducement Grant") to Micah Young, the Company's Chief Financial Officer and principal financial officer. The Inducement Grant was granted pursuant to the Company's 2026 Inducement Plan and as an inducement material to Mr.
QuidelOrtho: Too Much Uncertainty Around Earnings Keeping Short-Interest Elevated
QuidelOrtho Corporation continues its steep decline, with over 40% losses since February and a $5B market cap drop since its 2022 merger. QDEL's Q4 and Q1 results both disappointed, with 2026 EPS guidance cut twice in three months and consensus now at $1.85 per share. Profitability struggles are compounded by rising debt, high inventory, weak Chinese sales, and a soft respiratory season, with no clear mitigation strategies outlined.
QuidelOrtho (QDEL) Moves 32.2% Higher: Will This Strength Last?
QuidelOrtho (QDEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
QuidelOrtho Appoints Micah Young as Chief Financial Officer
Seasoned medical technology finance executive brings more than two decades of leadership at global public companies SAN DIEGO, June 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho" or the "Company"), a leading global provider of diagnostic solutions, today announced the appointment of Micah Young as Chief Financial Officer, effective July 6, 2026. Mr. Young will succeed Joseph M.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
QDEL's strong portfolio, cost-saving progress and mixed first-quarter results support growth, though respiratory reliance remains a risk.
Is QuidelOrtho Corp (QDEL) a Bargain After 3.3% Drop? GF Value Says Undervalued
On June 16, 2026, QuidelOrtho Corp (QDEL) shares fell 3.3%, bringing the current price to $14.13. The stock has experienced significant volatility, with a 52-we
Is the Options Market Predicting a Spike in QuidelOrtho Stock?
Investors need to pay close attention to QDEL stock based on the movements in the options market lately.
QuidelOrtho (QDEL) Up 24.1% Since Last Earnings Report: Can It Continue?
QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock?
QuidelOrtho's Respiratory Exposure Remains a Key Near-Term Risk
QDEL's Q1 results show how a milder respiratory season can pressure revenue, margins and cash flow despite stable testing market share.
QuidelOrtho and Allo Hope Foundation Join Forces to Advance Education, Connection and Early Testing for Alloimmunized Pregnancies
SAN DIEGO, June 2, 2026 /PRNewswire/ -- QuidelOrtho, a global leader in diagnostic innovation, and the Allo Hope Foundation, a nonprofit dedicated to supporting families and clinicians managing maternal alloimmunization, announced a new collaboration focused on improving prenatal care through education, early testing and stronger connections between laboratory providers, clinicians and patients. Maternal red blood cell alloimmunization is a serious, often misunderstood condition that can pose significant risks to the child during pregnancy.
A Look at QuidelOrtho Corp (QDEL) After 6.0% Gain -- GF Value $37.21 vs Price $13.06
On May 28, 2026, QuidelOrtho Corp (QDEL) shares rose 6.0% today, bringing the current price to $13.06. Over the past year, the stock has experienced significant
When Blood Compatibility Becomes a Pregnancy Risk
SAN DIEGO, May 21, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 58 of its Science Bytes podcast, focusing on hemolytic disease of the fetus and newborn (HDFN) – a serious but often underrecognized condition driven by maternal alloimmunization. Hosted by Michelle Mullens, Global Product Manager of Portfolio Solutions for Transfusion Medicine at QuidelOrtho, the episode features Bethany Weathersby, Founder and Executive Director of the Allo Hope Foundation.
QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences
SAN DIEGO, May 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today that members of its management team will participate in two upcoming investor conferences: William Blair 46th Annual Growth Stock Conference, Tuesday, June 2, 2026 Members of QuidelOrtho's management team will participate in a presentation at 12:20 p.m. ET / 9:20 a.m.
Price Targets
QuidelOrtho price target lowered to $12 from $17 at UBS
$12.00
(was $10.74)
Lu Li
·
UBS
QuidelOrtho downgraded to Hold from Buy at Jefferies
$12.50
(was $10.96)
Tycho Peterson
·
Jefferies
QuidelOrtho price target lowered to $17 from $30 at UBS
$17.00
(was $13.94)
UBS
QuidelOrtho price target lowered to $30 from $35 at UBS
$30.00
(was $23.19)
UBS
QuidelOrtho price target raised to $35 from $31 at UBS
$35.00
(was $32.73)
UBS
QuidelOrtho assumed with Neutral from Sell at UBS
$50.00
(was $46.23)
Lu Li
·
UBS
Craig-Hallum Upgrades Quidel Corp. (QDEL) to Buy
$57.00
(was $42.93)
Bill Bonello
·
Craig-Hallum
Analyst Is Frustrated By QuidelOrtho's Reduction In Guidance - Here's Why
$110.00
(was $74.47)
Andrew Cooper
·
Raymond James
Citigroup Upgrades QuidelOrtho to Buy, Raises Price Target to $125
$125.00
(was $92.30)
Citigroup
RBC Capital Initiates Coverage On QuidelOrtho with Outperform Rating, Announces Price Target of $125
$125.00
(was $92.19)
RBC Capital
UBS Upgrades Quidel Corp. (QDEL) to Neutral
$86.00
(was $76.38)
Elizabeth Garcia
·
UBS